AMPH - Amphastar Pharmaceuticals Inc Stock Price, Fair Value and News

43.48USD+0.74 (+1.73%)Delayed

Market Summary

USD43.48+0.74

Delayed

1.73%

AMPH Alerts

Big jump in Earnings (Y/Y)

AMPH Stock Price

View Fullscreen

AMPH RSI Chart

AMPH Valuation

Market Cap

2.1B

Price/Earnings (Trailing)

13.75

Price/Sales (Trailing)

3.14

EV/EBITDA

10.23

Price/Free Cashflow

13.21

AMPH Price/Sales (Trailing)

AMPH Profitability

Operating Margin

54.33%

EBT Margin

27.46%

Return on Equity

23.01%

Return on Assets

9.83%

Free Cashflow Yield

7.57%

AMPH Fundamentals

AMPH Revenue

Revenue (TTM)

676.2M

Rev. Growth (Yr)

22.72%

Rev. Growth (Qtr)

-3.52%

AMPH Earnings

Earnings (TTM)

154.7M

Earnings Growth (Yr)

65.86%

Earnings Growth (Qtr)

19.38%

Breaking Down AMPH Revenue

Last 7 days

3.0%

Last 30 days

8.6%

Last 90 days

-19.6%

Trailing 12 Months

-0.8%

How does AMPH drawdown profile look like?

AMPH Financial Health

Current Ratio

2.18

Debt/Equity

0.88

Debt/Cashflow

0.33

AMPH Investor Care

Shares Dilution (1Y)

1.30%

Diluted EPS (TTM)

2.91

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	676.2M	0	0	0
2023	518.6M	540.9M	601.3M	644.4M
2022	455.1M	476.9M	484.9M	499.0M
2021	368.2M	384.0M	412.8M	437.8M
2020	327.3M	334.0M	337.3M	349.8M
2019	316.1M	324.1M	328.7M	322.4M
2018	241.9M	247.8M	265.4M	294.7M
2017	252.5M	249.6M	243.3M	240.2M
2016	254.0M	268.2M	268.5M	255.2M
2015	221.5M	226.3M	230.5M	251.5M
2014	222.6M	209.1M	209.5M	210.5M
2013	210.7M	217.0M	223.3M	229.7M
2012	0	0	0	204.3M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Amphastar Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 01, 2024	petersen floyd f.	sold	-20,836	41.6739	-500	-
Apr 01, 2024	petersen floyd f.	sold	-21,714	43.4283	-500	-
Mar 17, 2024	zhou rong	sold (taxes)	-84,421	43.05	-1,961	senior evp, production center
Mar 17, 2024	zhang jack y.	sold (taxes)	-303,589	43.05	-7,052	ceo & chief scientific officer
Mar 17, 2024	zhang jack y.	sold (taxes)	-678,812	43.05	-15,768	ceo & chief scientific officer
Mar 17, 2024	liawatidewi yakob	sold (taxes)	-74,304	43.05	-1,726	evp corp admin center
Mar 17, 2024	peters william j	sold (taxes)	-183,178	43.05	-4,255	cfo, evp & treasurer
Mar 16, 2024	peters william j	sold (taxes)	-219,770	43.05	-5,105	cfo, evp & treasurer
Mar 16, 2024	liawatidewi yakob	sold (taxes)	-71,936	43.05	-1,671	evp corp admin center
Mar 16, 2024	zhou rong	sold (taxes)	-101,383	43.05	-2,355	senior evp, production center

Which funds bought or sold AMPH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	HANCOCK WHITNEY CORP	added	58.42	29,727	268,160	0.01%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-25.24	-1,508,560	1,706,340	-%
May 16, 2024	COMERICA BANK	reduced	-7.03	-352,623	684,601	-%
May 16, 2024	B. Riley Wealth Advisors, Inc.	sold off	-100	-409,942	-	-%
May 16, 2024	Virtus Investment Advisers, Inc.	unchanged	-	-109,596	268,246	0.19%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-7.01	-865,045	1,680,390	-%
May 15, 2024	D. E. Shaw & Co., Inc.	sold off	-100	-4,767,400	-	-%
May 15, 2024	ZACKS INVESTMENT MANAGEMENT	sold off	-100	-1,253,560	-	-%
May 15, 2024	Penserra Capital Management LLC	sold off	-100	-3,015,000	-	-%
May 15, 2024	TWINBEECH CAPITAL LP	new	-	5,140,500	5,140,500	0.11%

Are Funds Buying or Selling AMPH?

Are funds buying AMPH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AMPH

No. of Funds

AMPH Alerts

Big jump in Earnings (Y/Y)

Unveiling Amphastar Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 06, 2024	federated hermes, inc.	4.52%	2,165,071	SC 13G/A
Feb 13, 2024	vanguard group inc	5.88%	2,814,710	SC 13G/A
Feb 09, 2024	zhang jack y.	26.2%	13,435,210	SC 13G/A
Jan 23, 2024	blackrock inc.	12.6%	6,037,158	SC 13G/A
Jan 17, 2024	federated hermes, inc.	6.83%	3,272,761	SC 13G/A
Feb 09, 2023	vanguard group inc	5.42%	2,621,807	SC 13G/A
Feb 01, 2023	federated hermes, inc.	6.80%	3,284,217	SC 13G/A
Jan 27, 2023	zhang jack y.	25.5%	13,110,695	SC 13G/A
Jan 26, 2023	blackrock inc.	14.6%	7,038,769	SC 13G/A
Jan 20, 2023	blackrock inc.	14.6%	7,038,769	SC 13G/A

Recent SEC filings of Amphastar Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 10, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
May 02, 2024	4	Insider Trading
May 01, 2024	144	Notice of Insider Sale Intent
Apr 19, 2024	DEFA14A	DEFA14A
Apr 12, 2024	DEFA14A	DEFA14A
Apr 12, 2024	DEF 14A	DEF 14A
Apr 12, 2024	ARS	ARS
Apr 02, 2024	4	Insider Trading
Apr 01, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Amphastar Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	372.2B	85.6B	6.82%	-1.69%	9.67	4.35	5.68%	202.39%
MRK	332.3B	61.4B	4.65%	15.09%	144.1	5.41	6.11%	-82.30%
AMGN	167.7B	29.5B	18.35%	39.38%	44.55	5.68	12.76%	-52.47%
PFE	162.3B	57.8B	12.71%	-21.46%	129.52	2.81	76.51%	-86.81%
GILD	84.4B	27.4B	1.23%	-13.37%	174.21	3.07	1.51%	-91.32%
TEVA	18.4B	16.0B	23.52%	97.09%	-37.29	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	0.67%	-19.91%	9.41	2.37	54.01%	364.56%
PRGO	4.1B	4.6B	-0.70%	-10.77%	-528.11	0.89	-0.06%	94.55%
BHC	2.5B	9.0B	-21.94%	-21.03%	-5.45	0.28	10.01%	-27.45%
AMPH	2.1B	676.2M	8.56%	-0.82%	13.75	3.14	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	15.12%	-18.85%	-4.35	2.06	24.65%	80.36%
TXMD	25.8M	1.3M	18.52%	-47.17%	-3.49	19.84	-98.14%	-104.71%
ACRX	18.4M	89.6M	6.93%	25.60%	-1.29	0.19	287.27%	-129.41%
AGRX	2.5M	21.5M	2.70%	-90.89%	-0.32	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

Amphastar Pharmaceuticals Inc News

Latest updates

Amphastar Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-3.5%	172	178	181	146	140	135	120	123	120	121	112	102	103	96.00	83.00	86.00	85.00	83.00	80.00	79.00	80.00
Cost Of Revenue	-0.3%	82.00	82.00	72.00	73.00	66.00	64.00	62.00	60.00	65.00	65.00	61.00	54.00	58.00	59.00	47.00	53.00	48.00	50.00	45.00	47.00	49.00
Gross Profit	-6.3%	90.00	96.00	108	73.00	74.00	71.00	59.00	63.00	56.00	56.00	51.00	47.00	45.00	37.00	37.00	33.00	37.00	33.00	35.00	32.00	31.00
Operating Expenses	-0.2%	42.00	42.00	36.00	36.00	40.00	33.00	35.00	39.00	34.00	32.00	26.00	37.00	35.00	34.00	33.00	36.00	29.00	34.00	33.00	31.00	34.00
S&GA Expenses	8.7%	9.00	9.00	6.00	7.00	7.00	5.00	5.00	6.00	6.00	4.00	5.00	4.00	5.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00
R&D Expenses	-16.5%	17.00	20.00	17.00	17.00	20.00	17.00	19.00	23.00	16.00	17.00	11.00	18.00	15.00	18.00	18.00	16.00	15.00	20.00	19.00	16.00	15.00
EBITDA Margin	4.9%	0.36*	0.35*	0.36*	0.30*	0.28*	0.28*	0.26*	0.29*	0.29*	0.24*	0.18*	0.11*	-	-	-	-	-	-	-	-	-
Interest Expenses	-8.9%	9.00	9.00	14.00	4.00	0.00	1.00	1.00	0.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income Taxes	-11.7%	4.00	5.00	14.00	6.00	7.00	7.00	7.00	6.00	4.00	7.00	7.00	6.00	1.00	-0.95	2.00	-0.07	2.00	0.00	1.00	14.00	-1.48
Earnings Before Taxes	15.8%	48.00	41.00	64.00	33.00	34.00	41.00	23.00	23.00	29.00	27.00	38.00	14.00	5.00	-6.74	7.00	-1.50	6.00	1.00	2.00	61.00	-3.63
EBT Margin	3.3%	0.27*	0.27*	0.28*	0.24*	0.23*	0.23*	0.21*	0.25*	0.24*	0.19*	0.12*	0.05*	-	-	-	-	-	-	-	-	-
Net Income	19.4%	43.00	36.00	49.00	26.00	26.00	34.00	16.00	17.00	24.00	20.00	30.00	8.00	5.00	-6.27	4.00	-0.19	4.00	-1.03	1.00	48.00	1.00
Net Income Margin	7.2%	0.23*	0.21*	0.22*	0.19*	0.18*	0.18*	0.16*	0.19*	0.18*	0.14*	0.09*	0.03*	-	-	-	-	-	-	-	-	-
Free Cashflow	222.4%	46.00	14.00	54.00	46.00	31.00	9.00	15.00	-3.15	45.00	34.00	-4.65	26.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	4.1%	1,574	1,513	1,545	1,378	774	742	727	724	716	672	652	666	646	631	614	600	573	587	586	601	545
Current Assets	13.4%	555	490	543	385	408	378	384	377	364	318	304	311	300	280	277	267	247	255	269	284	230
Cash Equivalents	39.6%	201	144	267	149	177	156	157	166	173	127	107	125	102	95.00	90.00	89.00	57.00	76.00	87.00	122	81.00
Inventory	9.1%	115	106	110	105	104	104	103	99.00	95.00	93.00	100	98.00	97.00	97.00	109	105	108	111	110	99.00	79.00
Net PPE	2.0%	289	283	281	279	243	238	233	238	243	244	243	253	253	260	246	238	231	234	222	220	215
Liabilities	3.3%	902	873	949	789	225	213	222	224	237	226	222	199	195	183	163	158	149	159	152	169	164
Current Liabilities	13.2%	255	225	258	251	106	95.00	102	104	114	104	98.00	125	127	112	97.00	93.00	83.00	90.00	87.00	101	112
Long Term Debt	0.8%	594	590	638	488	73.00	73.00	74.00	74.00	74.00	75.00	76.00	30.00	32.00	34.00	33.00	35.00	36.00	39.00	38.00	40.00	31.00
Shareholder's Equity	5.2%	672	639	595	589	549	529	505	499	480	446	430	467	451	449	451	442	423	428	434	432	380
Retained Earnings	10.5%	452	409	373	324	298	272	238	222	205	180	161	131	123	118	124	120	120	116	117	116	68.00
Additional Paid-In Capital	-2.1%	476	486	478	471	457	455	449	443	433	422	413	427	414	410	404	397	371	367	362	355	349
Shares Outstanding	1.6%	49.00	48.00	48.00	49.00	48.00	48.00	49.00	49.00	48.00	48.00	48.00	48.00	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	45.00	45.00	46.00	46.00	45.00	46.00	46.00	44.00	44.00	45.00
Float	-	-	-	-	1,487	-	-	-	885	-	-	-	482	-	-	-	567	-	-	-	638	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	131.7%	55,291	23,864	64,334	54,923	40,382	15,226	20,375	2,815	50,765	40,441	2,569	32,159	22,825	16,893	8,807	30,089	1,477	5,652	-12,003	51,723	-3,610
Share Based Compensation	59.2%	7,360	4,622	4,644	4,865	6,111	4,304	4,299	4,235	5,022	3,850	3,919	6,084	4,834	4,333	4,370	6,513	5,282	4,295	4,294	4,032	4,674
Cashflow From Investing	114.8%	15,237	-103,049	-31,152	-508,582	-6,333	-229	-15,258	-8,180	-9,110	-11,954	-3,769	-4,254	-8,695	-12,176	-5,451	-10,066	-8,722	-7,352	-18,622	-9,669	-14,884
Cashflow From Financing	71.2%	-13,579	-47,083	86,613	428,111	-13,548	-16,162	-13,931	-994	4,648	-8,696	-16,492	-5,191	-6,639	-227	-3,026	12,456	-11,449	-10,382	-3,888	-742	11,229
Buy Backs	-	-	-	50,001	128	8,015	18,069	14,494	6,117	1,229	13,436	6,093	5,561	3,783	3,390	4,329	5,756	10,950	13,777	4,426	1,073	3,015

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AMPH Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Net Revenues:
Total net revenues	$ 171,836	$ 140,022
Cost of revenues	81,736	66,182
Gross profit	90,100	73,840
Operating expenses:
Selling, distribution, and marketing	9,371	7,109
General and administrative	15,676	13,483
Research and development	17,043	19,815
Total operating expenses	42,090	40,407
Income from operations	48,010	33,433
Non-operating income (expenses):
Interest income	2,556	924
Interest expense	(8,611)	(398)
Other income (expenses), net	5,921	(390)
Total non-operating income (expenses), net	(134)	136
Income before income taxes	47,876	33,569
Income tax provision	4,126	6,752
Income before equity in losses of unconsolidated affiliate	43,750	26,817
Equity in losses of unconsolidated affiliates	(573)	(785)
Net income attributable to Amphastar Pharmaceuticals, Inc.	43,177	26,032
Net income attributable to Amphastar Pharmaceuticals, Inc.	$ 43,177	$ 26,032
Net income per share
Basic (in Dollars per share)	$ 0.90	$ 0.54
Diluted (in Dollars per share)	$ 0.81	$ 0.50
Weighted-average shares used to compute net income per shares
Basic (in Shares)	48,212	48,000
Diluted (in Shares)	53,013	51,970
Product revenues, net
Net Revenues:
Total net revenues	$ 157,629	$ 140,022
Other revenues
Net Revenues:
Total net revenues	$ 14,207

AMPH Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 201,148	$ 144,296
Restricted cash	235	235
Short-term investments	88,407	112,510
Restricted short-term investments	2,200	2,200
Accounts receivable, net	138,114	114,943
Inventories	115,494	105,833
Income tax refunds and deposits	784	526
Prepaid expenses and other assets	8,696	9,057
Total current assets	555,078	489,600
Property, plant, and equipment, net	288,523	282,746
Finance lease right-of-use assets	516	564
Operating lease right-of-use assets	31,352	32,333
Investment in unconsolidated affiliate		527
Goodwill and intangible assets, net	607,064	613,295
Long-term investments	15,163	14,685
Other assets	23,369	25,910
Deferred tax assets	53,252	53,252
Total assets	1,574,317	1,512,912
Current liabilities:
Accounts payable and accrued liabilities	116,697	93,366
Accrued payments for BAQSIMI	128,245	126,090
Income taxes payable	5,857	1,609
Current portion of long-term debt	428	436
Current portion of operating lease liabilities	3,942	3,906
Total current liabilities	255,169	225,407
Long-term reserve for income tax liabilities	6,066	6,066
Long-term debt, net of current portion and unamortized debt issuance costs	594,006	589,579
Long-term operating lease liabilities, net of current portion	28,739	29,721
Other long-term liabilities	17,981	22,718
Total liabilities	901,961	873,491
Commitments and Contingencies
Stockholders' equity:
Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding
Common stock: par value $0.0001; 300,000,000 shares authorized; 60,160,459 and 48,841,343 shares issued and outstanding as of March 31, 2024 and 59,390,194 and 48,068,881 shares issued and outstanding as of December 31, 2023, respectively	6	6
Additional paid-in capital	476,072	486,056
Retained earnings	452,445	409,268
Accumulated other comprehensive loss	(8,769)	(8,478)
Treasury stock	(247,398)	(247,431)
Total equity	672,356	639,421
Total liabilities and stockholders' equity	$ 1,574,317	$ 1,512,912

About Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API). It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation; and Vasopressin to increase blood pressure in adults with vasodilatory shock. Further, the company distributes recombinant human insulin APIs and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

CEO	Dr. Yongfeng Zhang Ph.D.
WEBSITE	amphastar.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	1615

Amphastar Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Amphastar Pharmaceuticals Inc? What does AMPH stand for in stocks?

AMPH is the stock ticker symbol of Amphastar Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amphastar Pharmaceuticals Inc (AMPH)?

As of Fri May 17 2024, market cap of Amphastar Pharmaceuticals Inc is 2.13 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMPH stock?

You can check AMPH's fair value in chart for subscribers.

What is the fair value of AMPH stock?

You can check AMPH's fair value in chart for subscribers. The fair value of Amphastar Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Amphastar Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AMPH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Amphastar Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether AMPH is over valued or under valued. Whether Amphastar Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Amphastar Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMPH.

What is Amphastar Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, AMPH's PE ratio (Price to Earnings) is 13.75 and Price to Sales (PS) ratio is 3.14. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMPH PE ratio will change depending on the future growth rate expectations of investors.